CURRENT & POTENTIAL TREATMENTS

After only 150+ years from first diagnosis... there is no cure at all for MND/ALS yet!!! This is astonishing. This is inhuman and simply unacceptable.

Also, due to lack of focus and willingness, some potential and promising traetments have been in trial phase for 10+ years! Something is not really working...

Current Treatments

Riluzole (Rilutek)

Riluzole, marketed as Rilutek, was the first treatment to be approved by the FDA for ALS in 1995. Rilutek is an orally swallowed pill. Its effects are modest, extending life by about two to three months. The drug aims to address issues associated with the neurotransmitter glutamate operates in a person's body. Destructive behavior of glutamate, called glutamate excitotoxicity, has been linked to ALS disease progression.

Edaravone (Radicava)

Edaravone, also known as Radicava, was approved by the FDA in May 2017. Radicava is administered via intravenous infusion. The drug aims to address oxidative stress occurring in the cells, which is thought to be caused by an overabundance of certain molecules of oxygen called “free radicals”. Once infused into a person's blood stream Radicava diffuses around their body finding those oxygen molecules and helping the body to dispose of them.

In a six month Phase 3 clinical trial in Japan, Radicava was shown to slow down the loss of physical function in people with ALS by 33% as compared to placebo. The greatest impact was seen in those who started getting infusions of the medication early on in their disease. There are ongoing studies assessing the extent to which Radicava extends survival in people with ALS.

Potential & Promising Treatments

Today, there are dozens of clinical trials evaluating potential treatments enrolling people with MND/ALS.

See our page dedicated to Target Companies for information on the most promising studies underway today in the world.